BioSpace News Archive

Kymera Therapeutics, Inc. today announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Multiply Labs and Fedegari Group Collaborate to Add Sterilization to Automated Cell Therapy Manufacturing for Eliminating Contamination Risks.

Adimab, LLC today announced that 12 new partner programs entered clinical development in 2023.

Critical Path Institute announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer.

Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington’s Disease (HD) and Alzheimer’s Disease (AD) participants.

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for a novel formulation to treat breast and ovarian cancer.

Castle Biosciences, Inc. today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023.

Levity Products, Inc., an innovative provider of catheter stabilizers, today announced a strategic partnership with Domrex Pharma, Inc., a North American leader in healthcare product distribution.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab).

McKesson to Present at the 42nd Annual J.P. Morgan Healthcare Conference.